SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,368,981 | -8.8% | 267,274 | -0.5% | 0.01% | -7.1% |
| Q2 2023 | $8,077,463 | -26.9% | 268,725 | -11.9% | 0.01% | -33.3% |
| Q1 2023 | $11,053,178 | +15.8% | 305,087 | +14.0% | 0.02% | 0.0% |
| Q4 2022 | $9,545,223 | +15.3% | 267,597 | +9.4% | 0.02% | +16.7% |
| Q3 2022 | $8,277,000 | +26.4% | 244,521 | +8.0% | 0.02% | +28.6% |
| Q2 2022 | $6,547,000 | -9.3% | 226,394 | +1.5% | 0.01% | -6.7% |
| Q1 2022 | $7,217,000 | +13.5% | 223,149 | +2.4% | 0.02% | +25.0% |
| Q4 2021 | $6,357,000 | +5.8% | 217,953 | -3.2% | 0.01% | -7.7% |
| Q3 2021 | $6,009,000 | -1.9% | 225,186 | +13.2% | 0.01% | -7.1% |
| Q2 2021 | $6,128,000 | +29.1% | 198,948 | +9.7% | 0.01% | +16.7% |
| Q1 2021 | $4,748,000 | -15.1% | 181,303 | -18.4% | 0.01% | -14.3% |
| Q4 2020 | $5,590,000 | +11.4% | 222,076 | -7.8% | 0.01% | -6.7% |
| Q3 2020 | $5,020,000 | -3.1% | 240,862 | +10.5% | 0.02% | -6.2% |
| Q2 2020 | $5,180,000 | +81.7% | 218,031 | +37.5% | 0.02% | +60.0% |
| Q1 2020 | $2,851,000 | -61.7% | 158,542 | -49.5% | 0.01% | -54.5% |
| Q4 2019 | $7,451,000 | -14.9% | 313,977 | -1.6% | 0.02% | 0.0% |
| Q3 2019 | $8,751,000 | +18.6% | 319,131 | +43.9% | 0.02% | -8.3% |
| Q2 2019 | $7,377,000 | +1.5% | 221,786 | +7.4% | 0.02% | 0.0% |
| Q1 2019 | $7,265,000 | -29.5% | 206,433 | -4.4% | 0.02% | -35.1% |
| Q4 2018 | $10,306,000 | +10.4% | 215,940 | +16.5% | 0.04% | +8.8% |
| Q3 2018 | $9,336,000 | -31.5% | 185,363 | -18.6% | 0.03% | -26.1% |
| Q2 2018 | $13,625,000 | +28.2% | 227,638 | -1.9% | 0.05% | +12.2% |
| Q1 2018 | $10,630,000 | +16.7% | 232,102 | +1.6% | 0.04% | +28.1% |
| Q4 2017 | $9,108,000 | -8.3% | 228,556 | -7.9% | 0.03% | -8.6% |
| Q3 2017 | $9,928,000 | -11.4% | 248,193 | -4.6% | 0.04% | -22.2% |
| Q2 2017 | $11,210,000 | +79.3% | 260,085 | +30.2% | 0.04% | +66.7% |
| Q1 2017 | $6,253,000 | +19.6% | 199,782 | -3.5% | 0.03% | +8.0% |
| Q4 2016 | $5,229,000 | +36.7% | 207,098 | +33.9% | 0.02% | +31.6% |
| Q3 2016 | $3,824,000 | +26.7% | 154,680 | +4.4% | 0.02% | +5.6% |
| Q2 2016 | $3,018,000 | +38.9% | 148,170 | +4.0% | 0.02% | +28.6% |
| Q1 2016 | $2,173,000 | -23.9% | 142,467 | -32.9% | 0.01% | -17.6% |
| Q4 2015 | $2,854,000 | +48.8% | 212,393 | +55.3% | 0.02% | -5.6% |
| Q3 2015 | $1,918,000 | +58.3% | 136,720 | +91.5% | 0.02% | +63.6% |
| Q2 2015 | $1,212,000 | – | 71,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |